Trial
NCT03496519
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Colorado, Denver
Collaborators
—
Condition
Solid Tumor, Adult
Intervention
Dose Escalation of Durvalumab and Trabectedin
Why stopped
Contract Issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-09